Glaxo, Top Ad Spender, Didn’t Publicize Avandia Risks
Posted by shutah on June 2, 2007
June 1 (Bloomberg)
GlaxoSmithKline Plc was the drug industry’s top advertiser last year, promoting its asthma and diabetes treatments to patients and doctors. Information the company didn’t make well known is now drawing more attention.
London-based Glaxo knew its Avandia diabetes pill posed a risk for heart and circulatory complications as early as 1999, when the medicine won U.S. approval. The cardiovascular concern wasn’t widely disseminated until May 21 when a Cleveland Clinic Foundation analysis reported that Avandia may cause a 43 percent higher risk of heart attacks than other drugs.
When asked …..
“Why would you publicize it?,” Glaxo Chief Executive Officer Jean-Pierre Garnier told reporters at the company’s annual meeting May 23 in London. “We don’t publicize every submission we make to the Food and Drug Administration.”
Deja Vu ??
Click here to read the rest of the article.